Central to their framework is the dynamic network biomarker (DNB) theory, a powerful analytical approach leveraging fluctuations and correlations within biomolecular networks as harbingers of disease transitions. Unlike conventional biomarkers that signal disease presence after onset, DNB detects critical tipping points by revealing sharp escalations in dynamic instability and interaction strengths in gene expression patterns or cellular states. Prior empirical validations showcased in the editorial demonstrate DNB’s impressive predictive capability, effectively anticipating influenza infections days before symptom onset and pinpointing transitions from benign to malignant cellular states with tumor progression prediction accuracy surpassing 80%. Such sensitivity to preclinical shifts represents a paradigm shift in early disease interception.

For clinicians burdened by immense workloads, the authors spotlight the revolutionary individual-specific edge-network analysis (iENA), an algorithmic advancement enabling the assessment of disease dynamics using a single patient’s longitudinal molecular data. This method circumvents the need for extensive control cohorts, thus enhancing clinical applicability. By transforming transcriptomic datasets into edge network representations and calculating transition probabilities at the individual level, iENA has yielded area-under-the-curve (AUC) metrics exceeding 0.9. This not only signals exceptional predictive reliability but also paves the way for bedside-compatible, personalized disease monitoring, facilitating prompt and targeted intervention strategies.

Crucially, the editorial introduces hybrid AI architectures that marry mechanistic physiological models with deep learning, bridging the gap between theoretical simulations and real-world patient variability. In managing type 1 diabetes, physiology-informed long short-term memory (LSTM) networks exemplify this integration by slashing blood-glucose prediction errors by over 55% compared to traditional simulators. These models function as sophisticated digital twins, replicating individual metabolic dynamics and enabling in silico testing of therapeutic regimens before clinical implementation—a breakthrough that promises to optimize personalized disease management and minimize trial-and-error in treatment protocols.

Expanding beyond metabolic disorders, the editorial sketches a future where temporal graph neural networks and Transformer architectures harness longitudinal electronic health records (EHRs) and multimodal datasets to elevate diagnostic accuracy and forecast multifaceted disease risks. For instance, enhancements of 10–15% in diagnostic prediction accuracy on the MIMIC-III dataset underscore the practical gains of temporal graph networks. Similarly, dynamic graph-based models derived from functional MRI data have shown potential in anticipating treatment outcomes for complex neurological conditions like tinnitus. Transformer-based models, employing hierarchical attention mechanisms, have demonstrated proficiency in predicting multi-disease susceptibilities, including diabetes and hypertension, thereby enabling more holistic risk stratification.

In stark contrast to fears about AI supplanting clinicians, Professor Bin Sheng, the editorial’s corresponding author, stresses that these innovations are conceived to augment—not replace—medical judgment. By furnishing early-warning indicators of disease trajectory changes, such tools empower healthcare providers to adopt proactive, preventive approaches, fundamentally shifting medicine from reactive symptom management toward anticipatory care. Yet, the editorial acknowledges that nuanced human expertise remains indispensable in interpreting dynamic data signals, integrating contextual factors, and guiding complex clinical decision-making.

Despite these advances, the authors candidly address formidable obstacles that must be overcome before deploying such systems widely. The heterogeneity of medical datasets and pervasive missing values threaten to generate spurious fluctuations and false-positive alerts, compromising reliability. A deeper methodological challenge involves the intrinsic limitation of current AI models to distinguish correlation from causation—critical in ensuring meaningful clinical inferences—highlighting the imperative incorporation of domain-specific knowledge and experimental validation into analytical frameworks. Furthermore, issues surrounding interpretability abound: while model-agnostic explanation tools like SHAP and LIME offer glimpses into decision processes, the full transparency of deep, layered architectures remains elusive. This opacity risks undermining clinician trust and, subsequently, real-world adoption.

Ethical and regulatory dimensions add complexity to the implementation landscape. Even with promising privacy-preserving strategies such as federated learning, residual risks to sensitive health data persist. The editorial also warns of algorithmic bias, cautioning that models initially trained on homogenous populations may inadvertently exacerbate healthcare disparities when applied to diverse or underrepresented groups. These concerns command urgent attention to ensure AI solutions promote equitable, rather than unequal, healthcare advances.

Looking forward, the editorial outlines an ambitious path centered on multimodal data integration and rigorous prospective validation. Synthesizing heterogeneous datasets—including omics, imaging, electronic health records, and wearable sensor data—via state-of-the-art Transformers, graph neural networks, and causal inference tools promises to unravel complex, individualized disease trajectories. Incorporating instrumental variables and counterfactual simulations offers avenues to move from associative to causal understanding, greatly enhancing predictive utility and therapeutic relevance. Equally critical is the commitment to robust, prospective clinical trials and real-world deployment across diverse healthcare environments to substantiate efficacy and ensure generalizability.

Published as open access in Intelligent Medicine, this editorial serves as both a scholarly beacon and a guiding framework for clinicians, data scientists, and healthcare strategists invested in the future of medical AI. By marrying intricate data analytics with clinical insight, it heralds a transformative era in which medicine evolves from static snapshots to dynamic narratives—empowering truly individualized care and early disease mitigation.

The editorial’s insights resonate deeply with the growing imperative to harness the full potential of big data in medicine. As healthcare systems globally grapple with escalating chronic disease burdens, aging populations, and resource constraints, the promise of anticipatory, dynamics-driven AI offers a beacon of hope. By focusing on early detection through robust modeling of biological and clinical changes over time, these approaches could revolutionize disease management paradigms and health outcomes worldwide.

Moreover, the fusion of mechanistic knowledge with cutting-edge machine learning embodies the next frontier in AI research—balancing prediction accuracy with interpretability and biological plausibility. This hybrid approach aligns perfectly with the clinical reality, where understanding underlying pathophysiology remains essential for personalized treatment decisions. Digital twins and in silico simulations stand to dramatically reduce trial-and-error, accelerating the delivery of optimized therapies.

While challenges related to data quality, causality inference, transparency, and ethics remain considerable, the editorial’s candid exposition calls for concerted collaboration across disciplines to surmount these barriers. It emphasizes that only through careful, prospective evaluation and inclusive, transparent development can these innovations translate from computational promise to clinical reality.

Ultimately, this visionary editorial underscores a profound evolution in medical AI—from reactive diagnostics to predictive, personalized healthcare—heralding a future where data-driven early warning systems empower clinicians and patients alike to achieve better health proactively and equitably.

Subject of Research: Not applicable
Article Title: Dynamics-driven medical big data mining: dynamic approaches to early disease forecasting and individualized care
News Publication Date: 26-Feb-2026
References: DOI: 10.1016/j.imed.2025.10.001

The mechanisms that underlie the aggregation-induced emission phenomenon are rooted in the molecular design of AIEgens. When these compounds are diluted in solution, their molecular units are typically in a non-emissive state due to intramolecular motions that dissipate energy. However, upon aggregation, these otherwise mobile units become restricted and lead to a significant increase in fluorescence. This transformation is not just a matter of aesthetics; enhanced fluorescence signals facilitate improved detection of disease markers and pathological changes in cellular environments. This unique property holds immense promise for early-stage diagnosis where subtle changes can be overlooked.

The versatility of AIEgens does not end with enhanced fluorescence. Researchers have exploited their photochemical properties to also enable simultaneous phototherapy, an emerging treatment modality that integrates diagnosis and therapy into a single framework. This capability reflects a significant paradigm shift toward the concept of theranostics — a combined therapeutic and diagnostic approach that could radically change how conditions like cancer are treated. As AIEgens allow for real-time monitoring of treatment responses through imaging, they serve as powerful agents in personalized medicine, where interventions are tailored based on individual patient responses.

Clinical and translational studies involving AIEgens have already shown promising results in the detection of various diseases, including cancer, infections, and cardiovascular disorders. From early-stage diagnosis to monitoring treatment efficacy, AIEgens aid healthcare professionals in navigating the complex parameters inherent in disease pathology. Their ability to target specific cellular processes allows for more tailored approaches to therapies, optimizing both outcomes and patient safety. For instance, in oncology, precise imaging of tumor margins could guide surgical interventions, augmenting traditional techniques with data-driven insights derived from AIE-enhanced fluorescence.

Despite their remarkable properties, the road to broad clinical adoption of AIEgens is not without obstacles. Researchers have encountered limitations in terms of biocompatibility, clearance rates from the body, and the potential for systemic toxicity with certain AIEgen formulations. The development of AIEgens that effectively balance these factors while retaining strong emission properties remains a significant challenge. Addressing these limitations is not merely a matter of technical prowess; it requires an interdisciplinary approach involving chemists, biologists, and clinicians working hand-in-hand to refine and optimize AIEgen designs for accurate and safe human applications.

Functionalization strategies emerge as critical components in the pursuit of making AIEgens suitable for clinical environments. Tailoring the chemical structures of AIEgens can effectively modulate their properties, enhancing their performance and ensuring minimal adverse effects on biological systems. By introducing specific functional groups, scientists can improve solubility in physiological environments, alter uptake mechanisms in target cells, and direct the localization of AIEgens to areas of interest in vivo. This level of customization is essential for expanding the range of applications for AIEgens beyond mere imaging to include quantifiable therapeutic effects and diagnostics in various fields.

The trend towards using AIEgens in phototheranostics opens exciting possibilities for future biomedical applications. Ongoing research continues to illuminate how these innovative materials can be integrated into existing diagnostic workflows and therapeutic protocols. Potential applications extend into other medical fields, including neurology, where the imaging of neural tissue and the monitoring of associated pathologies could greatly benefit from AIE-enhanced visibility. Moreover, their use in detecting infectious agents or monitoring cardiovascular health translates to potentially revolutionary outcomes in preventative medicine.

While many integral aspects of AIEgen technology show promise, it is imperative to maintain an eye on sustainability and eco-friendliness as the materials are produced and utilized in therapeutic settings. Addressing the environmental impact of producing AIEgens and ensuring that their breakdown products do not introduce new hazards into biological systems will be crucial as the technology advances. The incorporation of sustainable practices into the development of AIE-based compounds will not only elevate their acceptance in the medical community but will also ensure compliance with broader ecological responsibility.

The growing adoption of AIEgens as integral components of disease management protocols illustrates the importance of collaboration in advancing this exciting scientific frontier. Partnerships among pharmaceutical companies, academic institutions, and clinical research organizations will catalyze innovation while also providing infrastructures necessary for clinical trials, regulatory approval, and eventual market entry. Feedback from clinical practice will, in turn, refine the strategies used to design and apply AIEgens effectively.

As efforts to bridge the gap between laboratory research and bedside application draw momentum, the potential for AIEgens to revolutionize disease diagnosis and management becomes increasingly tangible. Their unique properties position them as promising candidates not only for researchers but also for those in clinical settings looking to enhance patient care strategies. It is clear that the future of AIEgens in medicine is not just a projection, but a developing reality, as ongoing research strives to optimize their designs and applications.

In summary, the integration of aggregation-induced emission luminogens into clinical practice signifies a major stride toward enhancing diagnostic and therapeutic modalities. The evidence supporting their efficacy points toward a new era in which diseases can be detected earlier and treated more effectively. As researchers continue to overcome current challenges and capitalize on their unique properties, the vision of a fully integrated phototheranostic strategy utilizing AIEgens stands within reach. This forward-thinking approach epitomizes the true potential of modern science to redefine patient care and improve outcomes on a global scale.

With these innovations, the landscape of medical diagnostics and treatment is poised for transformation. The compelling potential of AIEgens serves not only to inspire further research and development but also to foster hope for advancing healthcare solutions that are more accurate, less invasive, and ultimately more successful in combating diseases that impact millions worldwide.

Subject of Research: Aggregation-Induced Emission Luminogens
Article Title: In vivo, clinical and translational aspects of aggregation-induced emission
Article References:

Yan, D., Wang, D. & Tang, B.Z. In vivo, clinical and translational aspects of aggregation-induced emission.
Nat Rev Bioeng (2025). https://doi.org/10.1038/s44222-025-00342-1

Image Credits: AI Generated
DOI: 10.1038/s44222-025-00342-1
Keywords: AIEgens, fluorescence imaging, phototheranostics, disease diagnosis, biomedical applications, biocompatibility, sustainable practices